AtRail Cardiopathy and Antithrombotic Drugs In prevention After cryptogenic stroke (ARCADIA)

Hooman Kamel, MD on behalf of the ARCADIA Investigators

ARCADIA

NIH StrokeNet
PREVENTION | TREATMENT | RECOVERY


NON-ATRIAL
STROKE
MECHANISMS
VASCULAR
RISK FACTORS
ABNORMAL
ATRIAL
SUBSTRATE
STROKE
ANTICOAGULATION
ATRIAL
FIBRILLATION

ARCADIA: Only [ESUS + Atrial Cardiopathy]

- AtRial Cardiopathy and Antithrombotic Drugs In prevention After cryptogenic stroke
- Hypothesis: apixaban is superior to aspirin for prevention of recurrent stroke in patients with ESUS and atrial cardiopathy

ARCADIA

NIH StrokeNet
PREVENTION | TREATMENT | RECOVERY

NDMC
Cassidy Conner
Catherine Dillon
Jessica Griffin
Erin Klintworth
Caitlyn Meinzer
Yuko Palesch
Wenle Zhao

NINDS
Scott Janis
Claudia Moy
Joanna Vivalda

PIs
Mitch Elkind
Hooman Kamel
Dick Kronmal
Will Longstreth
David Tirschwell

NCC
Joe Broderick
Elizabeth Costea
Irene Ewing
Jamey Frasure
Judy Spilker
Lindsay Vandergriff

CORES
Marco Di Tullio - ECHO
Eldad Hod - LAB
Sayed Soliman - ECG

SAFETY MONITOR
David Gladstone

VA
Seemant Chaturvedi

SUPPORT
BMS-Pfizer
Roche



ARCADIA

NIH StrokeNet
PREVENTION | TREATMENT | RECOVERY

Timeline

- Nov 2017 Investigator meeting
- Dec 2017 CRFs completed, WebDCU programmed
- Jan 2018 First site approved by cIRB
- Jan/Feb 2018 Complete protocol trial agreements, IRB clearances
- Feb 2018 Anticipated first enrollment

Contemporary Reviews in Cardiovascular Medicine

Evaluating the Atrial Myopathy Underlying Atrial Fibrillation

Identifying the Arrhythmogenic and Thrombogenic Substrate

Jeffrey J. Goldberger, MD, MBA; Rishi Arora, MD; David Green, MD, PhD; Philip Greenland, MD; Daniel C. Lee, MD, MSc; Donald M. Lloyd-Jones, MD, ScM; Michael Markl, PhD; Jason Ng, PhD; Sanjiv J. Shah, MD

REVIEW TOPIC OF THE WEEK

Fibrotic Atrial Cardiomyopathy, Atrial Fibrillation, and Thromboembolism

Mechanistic Links and Clinical Inferences

Benjamin J. Hirsh, MD, Robert S. Copeland-Halperin, MD, Jonathan L. Halperin, MD

EDITORIAL COMMENT

Is Atrial Fibrillation a Necessary Component of the Thrombogenic Atrium?*

Saman Nazarian, MD, PhD,[a] Tarek Zghaib, MD[b]

Comments and Opinions

Atrial Fibrillation and Mechanisms of Stroke

Time for a New Model

Hooman Kamel, MD; Peter M. Okin, MD; Mitchell S.V. Elkind, MD, MS; Costantino Iadecola, MD

Received October 28, 2015.
From the Feil Family Brain and Mind Research Institute (H.K., C.I.) and Division of Cardiology (P.M.O.), Weill Cornell Medicine, New York, NY; and Department of Neurology, College of Physicians and Surgeons, and Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, NY (M.S.V.E.).
The opinions expressed in the article are not necessarily those of the editors or of the American Heart Association.
Guest Editor for this article was Seemant Chaturvedi, MD.
Correspondence to Hooman Kamel, MD, 407 E 61st St, New York, NY 10065. E-mail hok9010@med.cornell.edu
(*Stroke*. 2016;47:895-900. DOI: 10.1161/STROKEAHA.115.012004.)

Stroke is available at http://stroke.ahajournals.org DOI: 10.1161/STROKEAHA.115.012004

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY VOL. 70, NO. 6, 2017

ISSN 0735-1097/$36.00
PUBLISHED BY ELSEVIER http://dx.doi.org/10.1016/j.jacc.2017.06.033

THE PRESENT AND FUTURE

REVIEW TOPIC OF THE WEEK

Atrial Cardiomyopathy

A Useful Notion in Cardiac Disease Management or a Passing Fad?

Jean-Baptiste Guichard, MD,[a,b] Stanley Nattel, MD[a,c,d]

Why Another ESUS Trial?

- RESPECT-ESUS
- NAVIGATE-ESUS

ARCADIA IS NOT JUST AN ESUS TRIAL!

ARCADIA = Different Question Than ESUS Trials

- ESUS likely a mix of occult cardiac and large-artery sources
  - Anticoagulation less likely to be effective for large-vessel disease
  - NAVIGATE-ESUS stopped early due to futility
- ESUS trials include patients with known or easily discoverable AF
  - Up to 6 minutes per day of AF allowed
  - No heart-rhythm monitoring after randomization

Promised Benefits of ARCADIA

- Establish biologically plausible, novel subset of ESUS
- Allow personalized treatment for preventing recurrent stroke
- Advance understanding of stroke pathogenesis
- Set stage for primary prevention trial in patients with atrial cardiopathy

twitter
@ARCADIA_trial

ARCADIA

NIH StrokeNet
PREVENTION | TREATMENT | RECOVERY